Drugs / E2
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT04372121 | Mar 2020 → Jan 2021 | endometriosis | Kissei Pharmaceutical Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT04335591 | Mar 2020 → Sep 2022 | endometriosis | Kissei Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02655146 Background | Dec 2015 → Dec 2016 | infertility disorder | Chong Qing Reproducive and Genetic Institute | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02655146 ↗ |
| Route | Oral | “with oral E2 (Progynova) 4-10mg/day at least 14 days.” NCT02655146 ↗ |